# Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population

> **NCT05966324** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 41 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** baxdrostat

## Key facts

- **NCT ID:** NCT05966324
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-07-05
- **Primary completion:** 2022-09-20
- **Final completion:** 2022-09-20
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2023-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05966324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05966324, "Baxdrostat Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in a Japanese Population". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05966324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*